Lisata Therapeutics wins new US patent for pancreatic cancer drug

Lisata Therapeutics (LSTA) received a new US patent for its drug certepetide, covering its use with anti-cancer agents to treat pancreatic cancer and other solid tumors. The patent expires in 2041, with market exclusivity until 2043. The company claims certepetide enhances drug delivery and tumor susceptibility to immunotherapies, showing promising safety and efficacy in trials.

Original reporting
Published Oct 8, 2026, 1:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lisata Therapeutics wins new US patent for pancreatic cancer drug — source image
Decision brief

The 30-second read

$LSTABullishLow
01

Why it matters

The new patent could extend the company's competitive moat and support future financing rounds.

02

Market read

A modest but material development for a micro‑cap biotech, likely to generate limited short‑term price movement.

03

What to watch

Regulatory approval timelines and competition from other delivery platforms could dilute the patent's value.

Relevance 5/10Novelty 6/10Timing: today

Background

Lisata Therapeutics focuses on peptide‑based drug delivery platforms for solid tumors.

Company-level read

Ticker impact

$LSTABullishMedium confidence
Context

Lisata Therapeutics was granted a new US patent for its experimental drug certepetide, extending market exclusivity to 2043.

Expected impact

potential upward pressure as investors price in extended exclusivity

Evidence & confidence

Patents are material for biotech firms; the new filing adds a layer of protection that may boost future cash flows.

Market effects

May improve sentiment toward pancreatic‑cancer therapeutics and related biotech peers.

Limited to US‑listed biotech investors.

Modest; primarily relevant to niche oncology investors.

Counterpoint

The patent may not translate into commercial success if clinical data remain inconclusive.

Key entities

  • Lisata Therapeutics Inc.

    Biotech firm developing the peptide drug certepetide.

Related articles

$LSTAMedAI 8/10

Lisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trial

Lisata Therapeutics' subsidiary Marea reported that its experimental antibody MAR001 reduced triglycerides by up to 72.2% in a Phase 2b trial, meeting all objectives. The trial involved 235 adults with severe hypertriglyceridemia. MAR001 also reduced remnant cholesterol and showed a safety profile comparable to placebo. Marea has started Part B of the trial and is developing a longer-acting version, MAR005.

$LSTAMedAI 8/10

Marea Therapeutics doses first patient in MAR002 phase 2 trial

Lisata Therapeutics' (LSTA) subsidiary Marea Therapeutics dosed the first patient in a Phase 2 trial for MAR002, a treatment for acromegaly. The trial aims to enroll 72 participants, with primary endpoint measuring IGF-1 reduction after 10 weeks. MAR002 could offer less frequent dosing than current treatments. Lisata's valuation may be impacted by clinical milestones, according to InvestingPro.

$LSTALow

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Marea Therapeutics, a subsidiary of Lisata Therapeutics (LSTA), dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. MAR002 is a potential best-in-class therapy that may enable dosing as infrequently as once every two weeks. The trial aims to enroll 72 participants, with a primary endpoint of IGF-1 reduction after 10 weeks of treatment.